MARKET

AMPE

AMPE

Ampio Pharma
AMEX

Real-time Quotes | Nasdaq Last Sale

0.1801
-0.0199
-9.95%
After Hours: 0.1851 +0.005 +2.78% 16:17 05/18 EDT
OPEN
0.1881
PREV CLOSE
0.2000
HIGH
0.2000
LOW
0.1750
VOLUME
5.16M
TURNOVER
50.01K
52 WEEK HIGH
2.000
52 WEEK LOW
0.1650
MARKET CAP
40.92M
P/E (TTM)
-2.1114
1D
5D
1M
3M
1Y
5Y
Ampio's Independent Committee Launches Investigation Related To AP-013 Trial
Benzinga · 1d ago
Ampio Pharmaceuticals: Q1 Earnings Insights
Ampio Pharmaceuticals (AMEX:AMPE) reported its Q1 earnings results on Monday, May 16, 2022 at 04:10 PM. Here's what investors need to know about the announcement.
Benzinga · 1d ago
Ampio Pharmaceuticals GAAP EPS of -$0.03 misses by $0.01
Ampio Pharmaceuticals press release (NYSE:AMPE): Q1 GAAP EPS of -$0.03 misses by $0.01. Cash and cash equivalents on March 31, 2022, totaled $28.8 million, compared to $33.9 million as of
Seekingalpha · 2d ago
BRIEF-Ampio Says FDA Does Not Consider Data From AP-013 Sufficient To Demonstrate Efficacy As Second Pivotal Trial
reuters.com · 2d ago
Ampio Pharma Reports An Independent Committee Will Conduction Investigation Related To Co.'s AP-013 Trial, Other Clinical Trials
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) ("Ampio" or the "Company") today announced that an independent special committee of the Ampio Board of Directors (the "Committee"), with the
Benzinga · 2d ago
BRIEF-Ampio Pharmaceuticals Reports First-Quarter Financial Results
reuters.com · 2d ago
Ampio Independent Committee to Conduct Investigation
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio" or the "Company") today announced that an independent special committee of the Ampio Board of Directors (the "Committee"), with the assistance of independent legal counsel, is in the process of con...
PR Newswire · 2d ago
Ampio Pharmaceuticals, Inc. to Hold Conference Call
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, announced th...
PR Newswire · 04/27 20:45
More
No Data
Learn about the latest financial forecast of AMPE. Analyze the recent business situations of Ampio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AMPE stock price target is 2.500 with a high estimate of 3.000 and a low estimate of 2.000.
High3.000
Average2.500
Low2.000
Current 0.1801
EPS
Actual
Estimate
-0.03-0.02-0.02-0.01
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 82
Institutional Holdings: 20.94M
% Owned: 9.22%
Shares Outstanding: 227.19M
TypeInstitutionsShares
Increased
13
1.36M
New
15
8.35M
Decreased
18
7.05M
Sold Out
15
1.46M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.37%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Martino
President/Chief Operating Officer
Holli Cherevka
Chief Financial Officer/Treasurer/Secretary
Daniel Stokely
Other
Howard Levy
Director
David Bar-Or
Director
J. Kevin Buchi
Independent Director
Philip Coelho
Independent Director
Richard Giles
Independent Director
Elizabeth Jobes
Independent Director
David Stevens
No Data
No Data
About AMPE
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. The Company's lead product candidate is Ampion, which contains a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease. Ampion is in development as an intra-articular injection treatment for severe osteoarthritis of the knee (OAK), an intravenous (IV) treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress. The Company is in the process of advancing clinical trials of Ampion in the United States. Ampion targets the cellular pathways in the innate immune response correlated with pain, inflammation, and joint damage in osteoarthritis.

Webull offers kinds of Ampio Pharmaceuticals Inc stock information, including AMEX:AMPE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPE stock methods without spending real money on the virtual paper trading platform.